[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496585":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":11,"id":54,"slug":11,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of Southern California","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Zolpidem","EXPERIMENTAL",null,[13],"Drug: Zolpidem Tartrate 10 mg",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Zolpidem Tartrate 10 mg","two days preoperatively and five days postoperatively",[9],{"type":21,"name":15,"description":23,"armGroupLabels":26,"otherNames":11},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Pui Yan, MS","CONTACT","323-442-6984","puiyan@med.usc.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Keck Medical Center of USC","RECRUITING","Los Angeles","California","90033","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-118.24368,34.05223,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Raymond Hah","Assistant Professor of Clinical Orthopaedic Surgery","100496585",false,"NCT05746143","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion: A Randomized Control Trial","Inclusion Criteria:\n\n* degenerative lumbar disease\n* age of 18-75\n* undergoing open primary one- to three-level lumbar fusion\n\nExclusion Criteria:\n\n* currently use a sleep aid nightly\n* diagnosed with insomnia or sleep apnea\n* history of delirium with opiates or zolpidem\n* allergic to opiates or zolpidem\n* had previous lumbar spine surgery\n* undergoing minimally invasive lumbar fusion,\n* undergoing lumbar fusion for fracture, infection, tumor, or an inflammatory spondyloarthropathy","ALL","18 Years","75 Years",{"count":64,"type":65},140,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.",[71,72,73,74],"Spine Fusion","Lumbar Spine Degeneration","Pain, Postoperative","Lumbar Spine Spondylosis",[76,9,77],"Lumbar Spine Fusion","Postoperative Outcomes","2026-04-29",{"date":80,"type":81},"2026-05-01","ACTUAL",{"date":83,"type":81},"2022-02-01",{"date":85,"type":65},"2030-12-31",{"name":5,"class":6},1]